GSA CAPITAL PARTNERS LLP

Position in VTRS — Viatris Inc

CIK 1362033 LONDON, X0

Position in VTRS

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$1,215,251

+$735,827 QoQ

Shares Held

89,952

+133.6% QoQ

Ownership

0.008%

of shares outstanding

% of Portfolio

0.09%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2022

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $10,107,066 across 16 Drug Manufacturers - Specialty & Generic names. VTRS ranks #3 (12.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	IRWD	Ironwood Pharmaceuticals Inc	654,445	$2,297,101
2	LQDA	Liquidia Corp	35,406	$1,336,222
3	VTRS	Viatris Inc This page	89,952	$1,215,251
4	NBIX	Neurocrine Biosciences Inc	6,688	$881,077
5	RGC	Regencell Bioscience Holdings Ltd	31,569	$802,799
6	XERS	Xeris Biopharma Holdings, Inc.	101,438	$588,340
7	SUPN	Supernus Pharmaceuticals, Inc.	10,556	$545,639
8	KNSA	Kiniksa Pharmaceuticals International, plc	11,257	$542,024

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,215,251	89,952	+133.6%	Shares	Sole	2026-05-08
2025-12-31	$479,424	38,508	-62.9%	Shares	Sole	2026-02-06
2025-09-30	$1,026,748	103,712	+151.0%	Shares	Sole	2025-11-07
2025-06-30	$368,987	41,320	-17.0%	Shares	Sole	2025-07-22
2025-03-31	$433,357	49,754	+24.8%	Shares	Sole	2025-05-08
2024-03-31	$476,155	39,879	-77.2%	Shares	Sole	2024-05-03
2023-09-30	$1,725,845	175,035	+477.2%	Shares	Sole	2023-11-15
2023-03-31	$291,716	30,324	-77.1%	Shares	Sole	2023-05-12
2022-09-30	$1,129,164	132,531	+180.7%	Shares	Sole	2022-11-14
2022-03-31	$513,720	47,217	—	Shares	Sole	2022-05-11
No filing history on record for this holder in this stock.